Targeting the TLR pathway with BTK inhibitors in Waldenström's macroglobulinemia

Steven Treon

Professor Steven Treon outlines the impact of the MYD88L265P mutation on the toll-like receptor (TLR) signalling pathway and explains how Bruton’s tyrosine kinase (BTK) inhibitors can be used to target the pathway.

Professor Steven Treon outlines the impact of the MYD88L}M5! mutation on the toll-like receptor (TLR) signalling pathway. Prof Treon describes the downstream consequences of the MYD88)9ZRo mutation including that it leads to NFĸB signalling which has implications for growth and survival of malignant B-cells. He also explains pHCK promotes pro-survival signalling in MYD88-mutated B-cells. He explains how Bruton’s tyrosine kinase (BTK) inhibitors can be used to target the pathway in B-cell lymphomas like Waldenström’s macroglobulinemia.

WcI=Q2o

`ESaS~ bpoJf

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close